ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:30 am ET. The conference is set to occur from September 12 to 14, 2022, at the Lotte New York Palace Hotel, with both in-person and virtual attendance options. An on-demand recording of the presentation will be available on ASLAN’s Investor Relations website starting September 12. Management will also hold one-on-one meetings with investors during the conference.
- None.
- None.
MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give an in-person company presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 am ET. The conference will be held from September 12 to 14, 2022, virtually and in-person at the Lotte New York Palace Hotel.
An on demand recording of the presentation will be available from September 12 at 10:30 am ET within the Investor Relations section of ASLAN’s website at www.ir.aslanpharma.com or can be accessed directly at this link.
Management will be available for one-on-one meetings with investors during the time of the conference. Please contact your representative at H.C. Wainwright to schedule a meeting.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
FAQ
When will ASLAN Pharmaceuticals present at the H.C. Wainwright 24th Annual Global Investment Conference?
Where is the H.C. Wainwright 24th Annual Global Investment Conference being held?
Will a recording of the ASLAN Pharmaceuticals presentation be available?
What are the dates of the H.C. Wainwright conference?
Will ASLAN Pharmaceuticals hold one-on-one meetings during the conference?
